Entresto is an FDA-approved heart failure drug owned by Novartis Pharms Corp. It contains two active ingredients: Sacubitril and Valsartan. This drug was authorized for market use on July 7, 2015, and has a total of 16 patents, five of which are expired.
The generic version of Entresto is expected to be available after May 9, 2036. The last patent for Entresto, US11058667, titled 'Sacubitril-valsartan dosage regimen for treating heart failure', will expire on this date. Therefore, no Entresto generic versions are expected on the market until after this date.
Entresto is used for the treatment of heart failure with preserved ejection fraction. It is also used for the treatment of chronic heart failure with reduced ejection fraction in patients who are not taking an ACE inhibitor or ARB, or those previously taking low doses of these agents. The drug works with its active ingredients Sacubitril and Valsartan that contribute significantly to its effectiveness.
Entresto, manufactured by Novartis Pharms Corp, holds a total of 16 patents, 5 of which have already expired. The remaining patents will gradually expire, with the last one, US11058667, expiring on May 9, 2036, paving the way for Entresto generic substitutes after this date. Below are the details of the patent: